The FDA has issued a drug shortage report for Foradil Aerolizer formoterol fumarate inhalation powder due to discontinuation of the product. According to the FDA website: "Novartis (manufacturer) and Merck have jointly decided to voluntarily discontinue manufacture of Foradil Aerolizer for business reasons. It is anticipated that inventory will be exhausted and no … [Read more...] about Foradil Aerolizer discontinued
News
GSK announces results from studies of Incruse Ellipta vs tiotropium and glycopyrronium
GlaxoSmithKline has announced data from two studies demonstrating that the Incruse Ellipta umeclidinium DPI produced statistically significant increase in FEV1 at 12 weeks in COPD patients compared to tiotropium and was non-inferior to glycopyrronium. GSK said that data from both 12-week randomized, blinded head-to-head studies will be presented at a future scientific … [Read more...] about GSK announces results from studies of Incruse Ellipta vs tiotropium and glycopyrronium
Similar hospital readmission rates for COPD patients using Brovana vs. fluticasone/salmeterol or tiotropium bromide
Sunovion is presenting data from retrospective database analyses in two separate posters at the 2015 American College of Chest Physicians annual meeting that show similar rates of hospital readmission for COPD patients treated with Brovana arformoterol tartrate inhalation solution compared to fluticasone/salmeterol or tiotropium bromide. Rates of 1-month all-cause … [Read more...] about Similar hospital readmission rates for COPD patients using Brovana vs. fluticasone/salmeterol or tiotropium bromide
Imprimis Pharmaceuticals acquires intranasal formulation compounding pharmacies
Imprimis Pharmaceuticals has announced the acquisition of what it says are the largest compounding pharmacies for sinus drugs in the US: Topical Apothecary Group, LLC (doing business as TAG Pharmacy), Aerosol Science Laboratories, Inc. (ASL Pharmacy), and SinuTopic, Inc. (Sinus Dynamics Pharmacy). Websites for all three are nearly identical, offering compounding of … [Read more...] about Imprimis Pharmaceuticals acquires intranasal formulation compounding pharmacies
Zephex propellant production facility celebrates 20th anniversary
Mexichem's Zephex HFA medical propellant manufacturing facility in Cheshire UK has celebrated its 20th anniversary, the company announced. The Cheshire cGMP facility, which opened in 1995, is audited by both the FDA and MHRA. According to Mexichem, 80% of metered dose inhalers worldwide currently use propellants, and over the past 20 years, Zephex propellants have … [Read more...] about Zephex propellant production facility celebrates 20th anniversary
Hovione acquires new formulation facility in Portugal
Hovione has acquired a formulation facility located next to its existing Loures, Portugal facility for process chemistry and particle engineering, the company said. The new facility will be able to produce clinical trial supplies and commercial batches for both oral and inhalation drug products, including highly potent APIs. Hovione VP of R&D Filipe Gaspar … [Read more...] about Hovione acquires new formulation facility in Portugal
Phase 2 trial of Verona’s RPL554 for the treatment of COPD gets underway
The first patients have been dosed in a Phase 2a study of Verona Pharma's RPL554 inhaled PDE3/PDE4 inhibitor as an addition to albuterol (salbutamol) and with ipratropium for the treatment of COPD, Verona said. The double-blind, placebo-controlled, six way crossover study will enroll up to 30 patients and will use the new suspension formulation of RPL554. Verona … [Read more...] about Phase 2 trial of Verona’s RPL554 for the treatment of COPD gets underway
Impel NeuroPharma gets investment from 3M New Ventures
Impel NeuroPharma has announced that 3M New Ventures (3M NV) led the investment in its $12 million Series B financing round to raise money for commercialization of Impel's Precision Olfactory Delivery (POD) platform. Impel recently announced a partnership with 3M Drug Delivery Systems for development and commercialization of the intranasal technology. Impel CEO … [Read more...] about Impel NeuroPharma gets investment from 3M New Ventures
Ferrer affirms commitment to Adasuve
Grupo Ferrer, which is partnered with Alexza Pharmaceuticals on Adasuve Staccato loxapine inhalation powder in the EU, Latin America, CIS nations, Middle East, North Africa, and parts of Asia, has reiterated its support for the product. Alexza announced in June 2015 that it would stop manufacturing Adasuve for its partners and in September said that it was considering … [Read more...] about Ferrer affirms commitment to Adasuve
Kristine Senft appointed VP Sales & Marketing at Hovione
Hovione has announced that Kristine Senft has joined the company as VP, Sales and Marketing and will succeed Dave Hoffman as VP, Sales and Business Development upon his retirement in April 2016. Senft, who was most recently VP, Regenerative Materials at DSM Biomedical, will be based in New Jersey, where Hovione recently announced that it would be doubling the size of … [Read more...] about Kristine Senft appointed VP Sales & Marketing at Hovione